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ROLE OF THE EPIGENETIC REGULATION OF CHROMATIN IN BREAST 
CANCER 
HISTONE MODIFICATIONS DNA METHYLATION 
The DNA methyltransferases transfer the methyl group from S-adenosyl 
methionine (SAM) to a cytosine of the dinucleotide CpG present in the 
human promoters. This modification is associated with silencing of 
genes due to a closer conformation of the chromatin. It has an 
important role in the regulation of transcription and it’s usually altered 
in malignant transformation. There are three active methyltransferases, 
one maintenance methyltransferase (DNMT1) and two 
methyltransferases de novo (DNMT3A and DNMT3B). 
 
HOW TO DETECT HISTONE MODIFICATIONS? 
HOW TO DETECT DNA METHYLATION? 
MAIN HISTONE MODIFICATIONS IN BREAST CANCER 
ALTERED GENES IN BREAST CANCER 
THERAPIES THERAPIES 
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Histone 
modification 
Gene 
expression 
Level Effect 
H3K9Ac Activates High Low lymph node state 
Low Large tumour size 
H4K16Ac Repress Low Large tumour size 
Positive vascular 
invasion 
H4R3Me2 Activates High Low lymph node state 
Low Large tumour size 
H3K27Me Repress High Poor prognosis 
DNA methylation Function  Genes 
Hypermethylation DNA repair BRCA1, MGMT, MuLL homolog 1 (MLH1), RAD9 
Metastasis Cadherin 13 (CDH13), Cystatin E/M (CST6), Spleen tyrosine kinase 
(SYK)  
Cell Cycle 
regulation 
Adenylate kinase 5 (AK5), Cyclin D2 (CCND2), Cyclin-dependent 
kinase inhibitors (CDKN1C and CDKN2A), ER, FOX2A, P16 INK4, 
Progesterone receptor (PR), Retinoic acid receptor (RAR), Ras 
association domain family protein 1 (RASSF1A), Runt-related 
transcription factor 3 (RUNX3), Stratifin (SFN), Secreted frizzled-
related protein 1 (SFRP1), WNT inhibitory factor 1 (WIF1), Wener 
Syndrome, RecQ helicase-like (WRN), Wilms tumour 1 (WT1) 
Apoptosis Adenomatous polyposis of the colon (APC), B-cell CLL/lymphoma 
2 (BCL2), Death-associated protein kinase  (DAPK), Deleted in 
colorectal carcinoma (DCC), Hypermethylated in cancer 1 (HIC1), 
Homeobox A5 (HOXA5), TMS1, TWIST 
Hypomethylation Metastasis Breast cancer-specific gene 1 protein (BCSG1), Caveolin 1 (CAV1), 
Cadherin (CDH1, CDH3), N-acetyltransferase 1 (NAT1), 
Plasminogen activator, urokinase (UPA)  
Histone acetylation enhances transcription and it is catalyzed by 
histone acetyltransferases. This modification is also involved in 
DNA repair. Histone deacetylation represses transcription and it is 
catalyzed by HDACs.  
Histone methylation silences tumour suppressor genes and the 
transcription of genes involved in DNA repair, chromatin 
remodelling, cell cycle regulation, metastasis, apoptosis, etc. This is 
the cause of the chromatin structure change; it’s catalyzed by DNA 
methyltransferases which maintain DNA methylation patterns. 
Histone phosphorilation is critical in DNA damage response, it’s 
catalyzed by kinases and it can activate/deactivate proteins. 
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Epigenetics are very important for developing Breast cancer due to their 
high frequency. This is related with the creation of new detection 
technologies helping to diagnose the illness. The reversibility of their 
effects is the clue to generate new effective therapies for the treatment.  
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CONCLUSIONS 
Therapies based on reverse the DNA methylation effects are 
those that use inhibitors of DNA methyltransferases (DNMTs). In 
breast cancer the two principals are 5-azacitidine and 5-aza-2’-
deoxixitidine (decitabine) approved by the FDA.  They 
incorporate themselves during the replication where in the DNA 
is a cytosine, generating a covalent union. Clinical results and 
biomarker evaluation of these therapies are ongoing. 
AZA single agent is in phase 2 in breast cancer primary operable. 
These therapies can be administered with chemotherapeutic 
agents like entinostat (phase 2) or tamoxifen (phase ½) in order 
to increase the effects.   
Therapies based on reverse histone modifications use inhibitors of  
histone deacethylases  (HDACi). They promote apoptosis in cancer cells 
and the reactivation of tumour suppressor genes and genes needed in 
cellular cycle. The developed HDACi are non selective. The main clinical 
results and biomarker evaluation are ongoing or unpublished yet. 
 
Vorinostat, a HDACi, inhibits proliferation and it is in Phase 2 to be 
approved for breast cancer (Vorinostat is tolerable and safe). It is used 
with chemotherapeutic agents like Tamoxifen (phase 2), aromatase 
inhibitor (phase 2), Trastuzumab (phase1/2) and Iapatinib (phase 1/2).  
 
Entinostat (MS-275) is another HDACi in phase 2 for breast cancer. It is 
used with Tamoxifen (phase 2) or Iapatinib (phase 1/2). 
